Open Access


Read more
image01

Online Manuscript Submission


Read more
image01

Submitted Manuscript Trail


Read more
image01

Online Payment


Read more
image01

Online Subscription


Read more
image01

Email Alert



Read more
image01

Original Research Article | OPEN ACCESS

Inhibition of SENP5 by cucurbitacin B suppresses cell growth and promotes apoptosis in osteosarcoma cells

Jiang-Bo Zhong1, Zhao-Rui Liu2 , Sen Liu3, Jian-Qiang Zhao3

1Department of Spine Surgery; 2Department of Orthopedics; 3Department of Oncology, Jinan Central Hospital Affiliated to Shandong University, Jinian, 250013, China.

For correspondence:-  Zhao-Rui Liu   Email: liuzhaorui276@gmail.com   Tel:+8653185695114

Received: 6 May 2015        Accepted: 5 August 2015        Published: 29 September 2015

Citation: Zhong J, Liu Z, Liu S, Zhao J. Inhibition of SENP5 by cucurbitacin B suppresses cell growth and promotes apoptosis in osteosarcoma cells. Trop J Pharm Res 2015; 14(9):1573-1579 doi: 10.4314/tjpr.v14i9.5

© 2015 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the effect of cucurbitacin B on the expression of SUMO-specific proteases (SENP5).
Methods: Effect of cucurbitacin B (10-50 mg/mL) on viability of U2OS and Saos-2 cells was determined in a plate reader by recording absorbance at 570 nm. In Western blot analysis, bicinconinic acid (BCA) method was used to determine protein concentration. Flow cytometry was employed to measure DNA content.
Results: Ccucurbitacin B treatment inhibits the expression of SENP5 in U2OS and Saos-2 osteosarcoma cells in a dose- and time-dependent manner. Significant inhibition (p = 0.005) of SENP5 expression was observed at 50 mg/ml from day 10, reaching a maximum on day 20. It also induced a significant decrease (p = 0.005) in mRNA and protein levels of SENP5. The decrease in mRNA and protein levels of SENP5 led to decrease in proliferation of U2OS and Saos-2 cells. The 48 h cell cultures containing 50 mg of cucurbitacin B caused induction of apoptosis in 54.72 ± 5.42 % of the total cell population in U2OS cells. Similarly, in Saos-2 cells, exposure to 50 mg/mL cucurbitacin B increased apoptotic rate from 9.86 ± 8.89 % for 10 mg/mL to 48.54 ± 14.5 % with 50 mg/mL of cucurbitacin B.
Conclusion: Cucurbitacin B is a potential therapeutic strategy for the treatment of aggressive malignancy in osteosarcoma.

Keywords: Cucurbitacin B, Osteosarcoma, SUMO-specific proteases, Cell proliferation, Apoptosis, Malignancy

Impact Factor
Thompson Reuters (ISI): 0.523 (2021)
H-5 index (Google Scholar): 39 (2021)

Article Tools

Share this article with



Article status: Free
Fulltext in PDF
Similar articles in Google
Similar article in this Journal:

Archives

2024; 23: 
1,   2,   3. 
2023; 22: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2022; 21: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2021; 20: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2020; 19: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2019; 18: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2018; 17: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2017; 16: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2016; 15: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2015; 14: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2014; 13: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12. 
2013; 12: 
1,   2,   3,   4,   5,   6. 
2012; 11: 
1,   2,   3,   4,   5,   6. 
2011; 10: 
1,   2,   3,   4,   5,   6. 
2010; 9: 
1,   2,   3,   4,   5,   6. 
2009; 8: 
1,   2,   3,   4,   5,   6. 
2008; 7: 
1,   2,   3,   4. 
2007; 6: 
1,   2,   3,   4. 
2006; 5: 
1,   2. 
2005; 4: 
1,   2. 
2004; 3: 
1. 
2003; 2: 
1,   2. 
2002; 1: 
1,   2. 

News Updates